Ontology highlight
ABSTRACT:
SUBMITTER: Sanghavi K
PROVIDER: S-EPMC6966186 | biostudies-literature | 2020 Jan
REPOSITORIES: biostudies-literature
Sanghavi Kinjal K Zhang Jason J Zhao Xiaochen X Feng Yan Y Statkevich Paul P Sheng Jennifer J Roy Amit A Vezina Heather E HE
CPT: pharmacometrics & systems pharmacology 20191201 1
Ipilimumab is a fully human monoclonal antibody approved for the treatment of melanoma as monotherapy and for the treatment of melanoma, renal cell carcinoma, and colorectal cancer in combination with nivolumab. Ipilimumab time-varying clearance (CL) was assessed by a population pharmacokinetics (PPK) model developed using statistically significant covariates identified in a previous PPK analysis plus additional covariates. Data from 3,411 patients who received ipilimumab 0.3-10 mg/kg alone or i ...[more]